NO20072803L - Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer - Google Patents

Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer

Info

Publication number
NO20072803L
NO20072803L NO20072803A NO20072803A NO20072803L NO 20072803 L NO20072803 L NO 20072803L NO 20072803 A NO20072803 A NO 20072803A NO 20072803 A NO20072803 A NO 20072803A NO 20072803 L NO20072803 L NO 20072803L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
vegf
receptor kinase
growth factor
vascular endothelial
Prior art date
Application number
NO20072803A
Other languages
English (en)
Norwegian (no)
Inventor
Karl-Heinz Thierauch
Martin Krueger
Martin Haberey
Holger Hess-Stumpp
Stuart Ince
Andreas Huth
Rolf Bohlmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20072803L publication Critical patent/NO20072803L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
NO20072803A 2004-11-03 2007-06-01 Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer NO20072803L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04090420A EP1655297A1 (fr) 2004-11-03 2004-11-03 Pyridineurées de nicotinamide commes inhibiteurs du recepteur kinase du facteur de croissance endothéliale vasculaire (VEGF)
PCT/EP2005/011709 WO2006048249A1 (fr) 2004-11-03 2005-10-28 Nicotinamide pyridinureas utiles comme inhibiteurs de kinase dans le recepteur du facteur de croissance de l'endothelium vasculaire (vegf)

Publications (1)

Publication Number Publication Date
NO20072803L true NO20072803L (no) 2007-08-02

Family

ID=34928841

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072803A NO20072803L (no) 2004-11-03 2007-06-01 Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer

Country Status (14)

Country Link
EP (2) EP1655297A1 (fr)
JP (1) JP5069119B2 (fr)
KR (1) KR20070085609A (fr)
CN (1) CN101056870A (fr)
AU (1) AU2005300734A1 (fr)
BR (1) BRPI0515725A (fr)
CA (1) CA2586265C (fr)
ES (1) ES2394324T3 (fr)
IL (1) IL182335A0 (fr)
MX (1) MX2007005340A (fr)
NO (1) NO20072803L (fr)
RU (1) RU2007120691A (fr)
WO (1) WO2006048249A1 (fr)
ZA (1) ZA200705003B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007311591B2 (en) 2006-10-18 2010-10-07 Pfizer Products Inc. Biaryl ether urea compounds
DK2346827T3 (da) * 2008-08-27 2014-02-03 Leo Pharma As Pyridinderivater som VEGFR-2 receptor og proteintyrosinkinasehæmmere
RU2017109664A (ru) 2009-10-06 2019-01-23 Милленниум Фармасьютикалз, Инк. Гетероциклические соединения, используемые в качестве ингибиторов pdk1
CA2927901A1 (fr) 2013-11-11 2015-05-14 Syngenta Participations Ag Derives de 1 -(pyridazin-3-yl)-imidazolidin-2-one en tant qu'herbicides
EP3092226B1 (fr) * 2014-01-10 2019-03-13 Aurigene Discovery Technologies Limited Composés d'imidazole utilisables en tant qu'inhibiteurs de l'irak4
DK3466955T3 (da) 2014-01-13 2021-02-01 Aurigene Discovery Tech Ltd Fremgangsmåde til fremstilling af oxazol[4,5-b]pyridin og thiazol[4,5-b]pyridinderivater som irak4-hæmmere til behandling af cancer
PL3600270T3 (pl) 2017-03-31 2023-09-25 Aurigene Oncology Limited Związki i kompozycje do leczenia zaburzeń hematologicznych
EP3704108B1 (fr) 2017-10-31 2024-04-24 Curis, Inc. Inhibiteur d'irak4 en combinaison avec un inhibiteur de bcl-2 pour utilisation dans le traitement du cancer
CN109942544B (zh) * 2017-12-21 2021-06-11 中国科学院合肥物质科学研究院 一类新型吲唑类衍生物激酶抑制剂
CN108467360B (zh) * 2018-06-22 2021-04-30 江苏美迪克化学品有限公司 一种阿帕替尼的制备方法及其中间体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2003000678A1 (fr) * 2001-05-08 2003-01-03 Schering Aktiengesellschaft Derives de cyanoanthranylamide et leur utilisation comme medicament
PL364478A1 (en) * 2001-05-08 2004-12-13 Schering Aktiengesellschaft Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
PL374610A1 (en) * 2002-07-31 2005-10-31 Schering Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
EP1655295A1 (fr) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinurées comme inhibiteurs de kinase du récepteur VEGF
EP1657241A1 (fr) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Nouveaux urées d' anthranylamide pyridine ayant une activité inhibitrice de kinase du récepteur de VEGF

Also Published As

Publication number Publication date
RU2007120691A (ru) 2008-12-10
KR20070085609A (ko) 2007-08-27
ES2394324T3 (es) 2013-01-30
EP1807416A1 (fr) 2007-07-18
CA2586265C (fr) 2013-08-06
CA2586265A1 (fr) 2006-05-11
MX2007005340A (es) 2007-08-17
JP2008518893A (ja) 2008-06-05
EP1655297A1 (fr) 2006-05-10
IL182335A0 (en) 2007-07-24
EP1807416B1 (fr) 2012-08-29
AU2005300734A1 (en) 2006-05-11
BRPI0515725A (pt) 2008-08-05
WO2006048249A1 (fr) 2006-05-11
CN101056870A (zh) 2007-10-17
JP5069119B2 (ja) 2012-11-07
ZA200705003B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
NO20072803L (no) Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer
NO20072802L (no) Nye antranilamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF) -reseptorkinaseinhibitorer
NO20072804L (no) Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer
WO2007050783A3 (fr) Fasudil en polytherapies pour traiter l'hypertension arterielle pulmonaire
CL2008003691A1 (es) Compuestos derivados de 4-(fenil o piridin) pirimidina, inhibidores de la elastasa neutrofila humana; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o la prevencion de hipertension arterial pulmonar, epoc, enfisema pulmonar, entre otras.
NO20090267L (no) Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20071593L (no) Pyrimidinderivater
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20064519L (no) Karbolinderivater som er anvendbare ved inhibering av angiogenese
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
NO20076648L (no) Novel thiophene derivatives
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
NO20082793L (no) Nye tiofenderivater
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
DK1543011T3 (da) Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander
NO20065948L (no) Quinazolin-4-yl-piperidin- and cinnolin-4-yl-piperidin-derivatives som PDE10-inhibitorer for behandling av CNS forstyrrelser
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20064771L (no) 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application